Here, I’m talking about the newest class of weight-loss drugs, the “GLP-1 drugs.” Indeed, the long-term impact of GLP-1 drugs has been a significant story in markets throughout 2023, but lately its had a big
It is also the active ingredient in Ozempic, which was the first of the weight loss jabs to blow up on TikTok. Read more: Ozempic to Wegovy: benefits and downsides Wegovy supply issues as private clinics stockpile How does semaglutide work? The National Institute for Care and...
Eithther the 22.7% or the 20.4% of patients’ body weight loss, on average, fell short of the 25% weight loss that Novo Nordisk projected previously for its next-generation drug. The company has predicted CagriSema will help patients lose “at least 25%” of their body weight. That wo...
Eithther the 22.7% or the 20.4% of patients’ body weight loss, on average, fell short of the 25% weight loss that Novo Nordisk projected previously for its next-generation drug. The company has predicted CagriSema will help patients lose “at least 25%” of their body weight. That would...
Swaps are discounting the chances of a -25 bp rate cut by the ECB at 100% for the September 12 meeting. US Stock Movers Diabetes device makers were under pressure Tuesday on the news that Eli Lilly’s weight-loss drug Zepbound helped cut the risk of diabetes by 94% in obese and pre...
Revenue from diabetes and weight loss drug Zepbound also surged to $2.3 billion in the quarter, up from $517 million a year ago. Analyst Sel Hardy says an aging population and growth in GLP-1 drug sales will create long-term tailwinds for Lilly. CFRA has a "buy" rating and $973 ...
think about stocks for a volatile market, a stock likeCoca-Cola(NYSE:KO) comes to mind. KO stock is down more than 17% in 2023. That could be the result of normalized growth or concerns about valuation. There’s also growing distaste for “snack stocks” in the age of weight loss ...
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy? Get Timely Buy & Sell Alerts With IBD Leaderboard Want More IBD Insights? Subscribe To Our Inves...
Investors haven't been bullish on the treatment, as recent trial data showed that it didn't achieve the 25% weight loss analysts were expecting, but it still has the potential to be a game changer for the business and the anti-obesity drug market. I believe investors are overreacting to...
The 10-year Treasury and 2-year Treasury are at their least inverted levels in more than two years. An inversion occurs when the shorter duration yield is higher than the longer duration yield. It has historically signaled a recession, though the current inversion has ...